This Specialty Chemical Stock Slips After Q1, But Brokerage Predicts 34% Rally

A specialty chemicals company surprised investors on Friday by delivering a strong set of quarterly earnings, yet its shares traded lower in early trading. The company reported double-digit growth across revenue, profit and operating margins, while a leading brokerage upgraded its earnings estimates and projected around 34% upside from the current market price. The contrasting market reaction has shifted investor attention from the day's price movement to the company's improving business fundamentals and growth outlook.

The company is Jubilant Ingrevia Ltd., whose shares traded at ₹733.60, down ₹8.95 or 1.21%, around 11:12 AM despite reporting a robust Q1 FY27 performance. Following the results, Anand Rathi reiterated its Buy rating and increased its target price to ₹980 from ₹975, citing stronger operating performance, improving margins and sustained growth across key business segments.

Jubilant Ingrevia Q1 FY27 Financial Performance

The latest quarterly results showed broad-based growth across the business. Consolidated revenue from operations increased 25.3% year-on-year to ₹1,300.3 crore, while net profit rose 41% to ₹106 crore during the June quarter.

EBITDA increased 40% year-on-year to ₹199.1 crore, while the EBITDA margin expanded to 15.3% from 13.7% in the corresponding quarter last year, reflecting improved operating efficiency and better product mix.

Quarterly Financial Snapshot

Metric	Q1 FY27	YoY Change
Revenue	₹1,300.3 Cr	+25.3%
Net Profit	₹106 Cr	+41%
EBITDA	₹199.1 Cr	+40%
EBITDA Margin	15.3%	Up from 13.7%

Why Did the Stock Fall Despite Strong Results?

Although the company reported better earnings, the stock traded lower during Friday's session. Short-term price movements often reflect profit booking, broader market sentiment or valuation adjustments rather than quarterly performance alone.

The brokerage noted that operating performance exceeded expectations, with quarterly EBITDA of around ₹2 billion coming in ahead of estimates, indicating that the underlying business remained stronger than the market reaction suggested.

Anand Rathi Raises Target Price

Following the earnings announcement, Anand Rathi maintained its Buy recommendation and increased its target price to ₹980, implying around 34% upside from the prevailing market price.

Brokerage View

Brokerage	Rating	Target Price	Implied Upside
Anand Rathi	Buy	₹980	~34%

Reflecting the improved outlook, the brokerage increased its FY27 EBITDA estimate by 7.5% and PAT estimate by 10.6%, while leaving FY28 estimates broadly unchanged.

What's Driving Growth?

According to Anand Rathi, the company's earnings were supported by multiple business drivers.

• Strong pricing across the Nutrition & Health Solutions (NHS) and Chemical Intermediates (CI) businesses.
• Higher volumes in Specialty Chemicals driven by Agro CDMO contracts.
• Faster ramp-up of human-grade Vitamin B3 and premixes in the NHS portfolio.
• Effective cost pass-through across major business segments.

The brokerage also noted that management maintained its FY27 EBITDA guidance of ₹7.5-8 billion, supported by higher Agro CDMO dispatches, expansion in Fine Chemicals, faster utilisation of new nutrition capacities and firm pricing in Chemical Intermediates.

Business Outlook

Management expects FY27 to benefit from improving operating leverage as recently commissioned assets scale up production. The upcoming multi-purpose plant and increasing contribution from higher-margin businesses are also expected to support earnings during the financial year.

The brokerage identified execution of Agro CDMO contracts and continued expansion in the Nutrition & Health Solutions business as the key drivers that could influence future earnings. It also noted that delays in CDMO execution remain an important business risk.

Company Overview

Jubilant Ingrevia Ltd. is a diversified specialty chemicals company operating across Specialty Chemicals, Nutrition & Health Solutions and Chemical Intermediates. The company serves industries including pharmaceuticals, agrochemicals, nutrition, consumer products and industrial chemicals through a diversified manufacturing portfolio.

Investor Takeaways

Jubilant Ingrevia reported a strong start to FY27, with 25.3% revenue growth, 41% growth in net profit, 40% EBITDA growth and margin expansion during the June quarter. While the stock traded lower immediately after the results, Anand Rathi maintained its Buy rating, raised its earnings estimates and increased the target price to ₹980, citing stronger operating performance, improving product mix and sustained growth across key business segments.

Why did Jubilant Ingrevia shares fall despite strong Q1 results?

The stock traded lower despite reporting strong quarterly earnings. Short-term market movements can be influenced by profit booking, broader market sentiment or valuation factors, even when financial performance improves.

What were Jubilant Ingrevia's Q1 FY27 results?

The company reported revenue of ₹1,300.3 crore, net profit of ₹106 crore, EBITDA of ₹199.1 crore and an EBITDA margin of 15.3% during the June quarter.

What is Anand Rathi's target price for Jubilant Ingrevia?

Anand Rathi maintained a Buy rating and raised its target price to ₹980, implying an upside of around 34% from the prevailing market price.

Why did Anand Rathi increase earnings estimates?

The brokerage cited strong pricing across key business segments, higher Agro CDMO volumes, faster growth in the Nutrition & Health Solutions business and improved operating leverage.

What guidance has Jubilant Ingrevia maintained for FY27?

Management maintained its FY27 EBITDA guidance of ₹7.5-8 billion, supported by higher Agro CDMO dispatches, Fine Chemicals expansion and continued growth in Nutrition & Health Solutions.